Vaccine introduction, policy and financing are complex issues, and countries must achieve ambitious immunization targets with limited available resources. To make informed decisions for the health of their people, decision makers need accurate, up-to-date information to identify vulnerable populations, assess burden of disease, evaluate vaccine efficacy and cost-effectiveness, and measure the efficiency of immunization programs.

Sabin works to establish best practices, tools and structures that help countries evaluate and streamline vaccine introduction and expansion. Sabin drives evidence generation through research, advocacy and education – conducting and supporting disease surveillance to establish the burden of diseases including dengue and typhoid, strengthening laboratory capacity for diagnosis and clinical trials, disseminating existing evidence to decision makers, piloting a more efficient surveillance technology in Paraguay, designing tools for economic analysis and more.

Using evidence generated in partnership with Sabin, countries around the world have accelerated access to immunization: Cameroon, DRC, Georgia, Mali and Vietnam have won budget increases for immunization, and countries in Latin America gained a better understanding of the disease burden for pertussis, leading Argentina to introduce a maternal dose of a pertussis vaccine.

Sabin helps countries make more informed decisions on immunization to strengthen their programs to reach every child.

Learn about Sabin’s evidence generation activities for other diseases:

Pertussis
HPV
Meningococcal Disease
Pneumococcal Disease
Dengue